Greater intakes of dairy are frequently associated with reduced risk of cardiovascular disease. These observational studies have served as the basis for controlled interventions aimed at defining the cardioprotective mechanisms of dairy. Understanding these relationships is of public health importance because most of the US population fails to meet dietary recommendations for dairy, suggesting that many individuals could lower their cardiovascular disease risk by relatively simple dietary modification. Clinical studies investigating the acute ingestion of dairy or its constituents, including short-term (≤2 week) supplementation studies or those assessing postprandial responses, have largely shown benefits on vascular function without concomitant improvements in blood pressure. Chronic interventions have been less conclusive, with some showing benefits and others indicating a lack of improvement in vascular function regardless of blood pressure changes. Vasoprotective activities of dairy are likely mediated through improvements in nitric oxide bioavailability, oxidative stress, inflammation, and insulin resistance. Future controlled studies are needed to determine if these health benefits are mediated directly by dairy or indirectly by displacing other dietary components that otherwise impair vascular health.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/nutrit/nuu013 | DOI Listing |
Int J Numer Method Biomed Eng
March 2025
College of Chemistry and Life Science, Beijing University of Technology, Beijing, China.
Superficial temporal artery and middle cerebral artery (STA-MCA) bypass surgery is an effective method to enhance cerebral blood flow (CBF) in ischemic patients. However, the effectiveness of various bypass techniques varies with the diversity of Circle of Willis (CoW) structures. This study aims to develop a physiologically realistic hemodynamic model to optimize STA-MCA bypass planning for cerebral ischemia patients with different CoW structures.
View Article and Find Full Text PDFPulmonary hypertension (PH) stands as a tumor paradigm cardiovascular disease marked by hyperproliferation of cells and vascular remodeling, culminating in heart failure. Complex genetic and epigenetic mechanisms collectively contribute to the disruption of pulmonary vascular homeostasis. In recent years, advancements in research technology have identified numerous gene deletions and mutations, in addition to , that are closely associated with the vascular remodeling process in PH.
View Article and Find Full Text PDFCirc Rep
March 2025
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan.
Background: Despite the development of effective pulmonary vasodilators, the prognosis for patients with pulmonary hypertension (PH) remains poor, particularly in medication-refractory patients. Catheter-based pulmonary artery denervation (PADN) is an emerging therapeutic strategy targeting the sympathetic nervous system in various types of PH. However, data on its safety and efficacy in refractory patients with PH who truly require non-pharmacotherapy are lacking.
View Article and Find Full Text PDFCirc Rep
March 2025
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute Osaka Japan.
Background: Because Regnase-1, encoded by , suppresses the development of pulmonary arterial hypertension (PAH) by controlling pro-inflammatory cytokines, we aimed to identify variants in patients with PAH.
Methods And Results: We analyzed whole-genome sequence data of patients with PAH to search for disease-associated variants. The Regnase-1 p.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!